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Concise review: programming human pluripotent stem cells
into blood
Jennifer Easterbrook, Antonella Fidanza and Lesley M. Forrester
MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
Summary
Blood disorders are treated with cell therapies including
haematopoietic stem cell (HSC) transplantation as well as
platelet and red blood cell transfusions. However the source
of cells is entirely dependent on donors, procedures are sus-
ceptible to transfusion-transmitted infections and serious
complications can arise in recipients due to immunological
incompatibility. These problems could be alleviated if it was
possible to produce haematopoietic cells in vitro from an
autologous and renewable cell source. The production of
haematopoietic cells in the laboratory from human induced
pluripotent stem cells (iPSCs) may provide a route to realize
this goal but it has proven challenging to generate long-term
reconstituting HSCs. To date, the optimization of differentia-
tion protocols has mostly relied on the manipulation of
extrinsic signals to mimic the in vivo environment. We
review studies that have taken an alternative approach to
modulate intrinsic signals by enforced expression of tran-
scription factors. Single and combinations of multiple tran-
scription factors have been used in a variety of contexts to
enhance the production of haematopoietic cells from human
pluripotent stem cells. This programming approach, together
with the recent advances in the production and use of syn-
thetic transcription factors, holds great promise for the pro-
duction of fully functional HSCs in the future.
Keywords: pluripotent stem cells, differentiation, hematopoi-
etic stem cells, hematopoietic progenitors cells, transcription
factors, programming.
The quest for engraftable HSCs
The generation of an unlimited supply of clinical-grade,
engraftable haematopoietic stem cells (HSCs) and fully func-
tional mature blood cells is a highly sought after goal for
clinical haematologists. HSC transplantation is currently the
most widely used regenerative therapy in clinical practice,
used as a potentially curative treatment for a wide range of
malignant and non-malignant conditions. The current major
source of HSCs is from peripheral blood following mobiliza-
tion from bone marrow (BM), with BM itself and umbilical
cord blood (UCB) providing alternative sources. However,
problems with all of these sources include a significant short-
age of appropriate donor supplies, the requirement for
immune compatibility and risk of transmission of infectious
or malignant disease. The ultimate goal of this field is there-
fore to produce a reliable and scalable source of HSCs cap-
able of efficient and complete long-term engraftment. In
addition to their direct therapeutic application for BM trans-
plantation, HSCs could provide a source of mature
haematopoietic cells for other therapeutic purposes such as
red blood cell and platelet transfusions and for drug testing
and modelling of both human development and haematolog-
ical malignancies.
Pluripotent stem cells (PSCs) could potentially provide the
answer to this quest (Table I). These cells are capable of
extensive self-renewal in the laboratory and can be differenti-
ated into any cell type of the body, including blood cells.
One type of PSC, known as human embryonic stem cells
(hESCs) is derived from the inner cell mass of the embryonic
blastocyst but, although they provide an excellent tool to
study human biology, ethical concerns associated with their
origin limit their use in the clinic. Hence the advent of
induced-pluripotent stem cells (iPSCs) led to great optimism
in the field as a potentially limitless source of clinical-grade,
immunologically-matched hematopoietic cells (Kaufman,
2009). Human iPSCs can be produced by reprogramming
mature adult cells, such as skin cells, into stem cells with the
‘pluripotency-associated transcription factor’-encoding genes,
POU5F1, KLF4, SOX2 and MYC (Takahashi et al, 2007).
Their extensive self-renewal capacity and ability to differenti-
ate into any cell type means that they can provide an autolo-
gous source for any cell type.
Attempts to generate haematopoietic cell types from iPSCs
and hESCs have thus far involved differentiation protocols
that include the step-wise addition of cytokines in serum-free
conditions, differentiation of PSCs in three-dimensional
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structures known as embryoid bodies (EBs) or co-culture on
stromal cells (Kaufman et al, 2001; Zambidis et al, 2005;
Kennedy et al, 2007; Ledran et al, 2008; Salvagiotto et al,
2011). There has been some success in producing multilin-
eage progenitors and cells that are capable of limited in vivo
reconstitution but there are no robust, reproducible proto-
cols that can generate long-term reconstituting HSCs. While
mature blood cells, such as macrophages (Choi et al, 2011),
dendritic cells, and erythrocytes (Kobari et al, 2012), can be
produced, these protocols also have significant limitations.
For instance, hESC-derived erythroid cells predominantly
express fetal rather than adult globins and fail to enucleate
efficiently (Mountford et al, 2010; Mazurier et al, 2011). It is
noteworthy that many of these studies report significant vari-
ations in the haematopoietic potential of different hESC/iPSC
lines in identical culture conditions suggesting that there are
specific intrinsic signals that regulate the production of
haematopoietic cells in vitro (Melichar et al, 2011). Could
manipulation of these intrinsic signals be the solution? While
it is clear that intrinsic signalling involves highly complex
genetic networks, specific master regulatory transcription fac-
tors (TFs) have been identified which regulate haematopoi-
etic development (Lessard et al, 2004; Teitell & Mikkola,
2006; Wilson et al, 2011). The production of HSCs from
human PSCs in vitro could be enhanced potentially by
manipulating the expression of these key TFs.
Genetic programming with transcription factors
The concept of TF programming, whereby overexpression of
master TFs in one cell type can convert the cell into a differ-
ent functional cell, was first demonstrated by the conversion
of murine fibroblasts to cells with myogenic properties with
the single TF-encoding gene, Myod1 (Davis et al, 1987).
However, arguably the most acclaimed example was the land-
mark report that fully differentiated somatic cells can be
reprogrammed to PSCs by the exogenous expression of just
four TFs (Takahashi & Yamanaka, 2006). TF programming
has also been used to produce haematopoietic progenitor
cells (HPCs)/HSCs either from a mature differentiated cell
type (herein referred to as direct programming) or from
PSCs (herein referred to as forward programming) (Fig 1).
Human dermal fibroblasts were converted to myeloid-
restricted multilineage HPCs in a direct programming strat-
egy by the ectopic expression of the pluripotency-associated
TFs, POU5F1 (Szabo et al, 2010) and SOX2 (Pulecio et al,
2014). Similarly, two studies demonstrated that murine
fibroblasts could be directly converted to HPCs using combi-
nations of haematopoietic TFs (Pereira et al, 2013; Batta
et al, 2014). These direct programming strategies will not be
discussed in detail here as an excellent review on this topic
has been published recently (Ebina & Rossi, 2015). However,
it is clear that this direct programming strategy has not been
able to generate robust long-term repopulating HSCs with
multilineage potential.
One approach to this problem has been to use a starting
cell that has a more similar epigenetic memory to functional
haematopoietic cells. For example, direct programming of
human umbilical vein and dermal microvascular endothelial
cells with FOSB, GFI1, RUNX1 and SPI1 resulted in the pro-
duction of multipotent HPCs capable of long-term engraft-
ment and serial transplantation. However, although a small
but significant population of T cells were generated in vitro
when the expression of SPI1 was temporally restricted, T cells
were not detected in engrafted recipients (Sandler et al,
2014). This study emphasized the importance of the
microenvironment as reprogrammed cells had to be propa-
gated within an instructive vascular niche to induce the out-
growth of multipotent HPCs.
Transient expression of Runx1, Hlf, Lmo2, Prdm5, Pbx1,
and Zfp37 in primary murine lymphoid and myeloid progen-
itors further supported the hypothesis that reducing the epi-
genetic barrier could provide a route to the successful
production of HSCs (Riddell et al, 2014). Cells with clonal
multilineage differentiation potential [termed induced-HSCs
(i-HSCs)] capable of serial transplantation were generated
using this strategy. However, although the TFs were delivered
to their target cells ex vivo, the cells were then returned to
the haematopoietic inductive microenvironment in vivo,
again highlighting the fact that the environment plays an
essential role in maturation and maintenance of repro-
grammed cells. While an exciting advance, this study
required HSCs to be selected and expanded in vivo and
clearly this type of strategy would be difficult to replicate
routinely in the clinical setting.
Forward programming of hPSCs
While different starting cells have been employed in an
attempt to ‘lower the epigenetic barrier’, human PSCs argu-
ably provide the best genomic landscape for successful pro-
duction of HSCs. Forward programming of human PSCs
with appropriate TFs is therefore an exciting prospect
Table I. Key definitions.
PSC Pluripotent stem cell Includes both ESCs and iPSCs
iPSC Induced pluripotent
stem cell




Derived from the inner cell mass
of a blastocyst




Capacity for long-term multilineage
engraftment & serial transplantation
HPC Haematopoietic
progenitor cell
Precursor cell lacking true HSC
properties above
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(Fig 1). In this review we highlight recent studies that have
used forward programming in both human ESCs and iPSCs
to enhance production of HPCs. We summarize the role of
the chosen TFs in haematopoiesis in vivo, describe the selec-
tion strategies & differentiation methods employed and dis-
cuss the reported effects on HPC/HSC production (Table II).
A number of strategies have used single TFs to enhance
haematopoietic differentiation but more recently combinato-
rial strategies involving multiple TFs have been used.
Forward programming of human PSCs with
single transcription factors
TAL1 (T cell acute lymphocytic leukaemia 1), also known as
SCL (stem cell leukaemia), is a critical haematopoietic regu-
lator that plays a key role in both embryonic and adult HSC
specification and its rearrangement is associated with several
human leukaemias (Lecuyer & Hoang, 2004). Mice carrying
a homozygous deletion of the Tal1 gene do not survive
beyond embryonic day 95 due to a failure of haematopoietic
development (Shivdasani et al, 1995) but its precise role
remains unclear. In one study, Tal1 was shown to be
indispensable for the establishment of the haemogenic
endothelium (HE) (Lancrin et al, 2009), but in another it is
allegedly dispensable for the development of the haeman-
gioblast but essential for subsequent haematopoietic commit-
ment (D’Souza et al, 2005).
The role of TAL1 in early human haematopoiesis has been
investigated using the hESC differentiation system (Yung
et al, 2011; Real et al, 2012). TAL1 was identified as being
the most highly upregulated transcript in the emerging hae-
mangioblast (CD31+CD309+ cells) during the first 4 days of
a feeder-free, serum-free hESC haematopoietic differentiation
protocol (Yung et al, 2011). Subsequent experiments, in
which the TAL1 cDNA was overexpressed more than 100-
fold in hESCs, demonstrated enhanced differentiation of
meso-endodermal lineages and increased differentiation to all
myeloid lineages. TAL1 overexpression also accelerated for-
mation of erythro-megakaryocytic progenitors and most
notably accelerated erythroid differentiation. Intra-splenic
transplantation of TAL1-overexpressing hESC-derived
haematopoietic cells enhanced recovery of immunocompro-
mised mice from induced acute haemolytic anemia but no
significant engraftment of cells was detected. The authors
Fig 1. Programming strategies employed for the production of human haematopoietic cells in vitro. The production of haematopoietic progeni-
tors cells (HPCs) from human pluripotent stem cells (PSCs) has been enhanced by the overexpression of single or multiple TFs (forward pro-
gramming). TFs have also been used to programme other mature cell types, such as endothelial cells and fibroblasts, into HPCs (direct
programming). The production of multilineage cells with serial transplantation capacity has been achieved in vitro (dotted arrow) but these cells
lacked T cell potential in vivo so it is premature to consider these as fully functional haematopoietic stem cells (HSCs). Classic reprogramming of
fibroblasts into PSCs with the four TFs reported by Takahashi et al., (2007) has been included for completeness. See text for references.
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suggested that the observation could indicate that overex-
pression of TAL1 might also have a paracrine effect compara-
ble to that reported for HOXB4 (Jackson et al, 2012) but this
clearly requires further investigation. TAL1 was also reported
to be expressed in hESCs-derived haemato-endothelial pro-
genitors (CD45-CD31+CD34+) and in CD45+ cells using an
OP9 co-culture differentiation system (Real et al, 2012).
Overexpression of TAL1 in that system accelerated the pro-
duction of the haemato-endothelial progenitors and the sub-
sequent differentiation into HPCs (CD34+CD45+) with
significant clonogenic potential, but these cells failed to
engraft in vivo. Silencing of endogenous TAL1 using shTAL1
Table II. Effect of transcription factor overexpression on production of HPCs and HSCs from human PSCs.






































































































































ND, Not determined; EB, Embryoid body; hESCs, human embryonic stem cells; hiPSCs, human induced-pluripotent stem cells; CFU-C, Colony-
forming unit in culture; CFU-E, CFU-Erythroid; CFU-G, CFU-Granulocyte; CFU-GEMM, CFU-granulocyte/erythroid/monocyte/megakaryocyte;
BFU-E, Blast-forming unit in culture-erythroid; HSC, Haematopoietic stem cell; HPC, Haematopoietic progenitor cell.
*With the exception of Doulatov et al (2013) who used hPSC-derived CD34+CD45+ as starting cells, these are all examples of forward program-
ming of human PSCs. All overexpression systems are constitutive unless specified otherwise.
†’HSC production’ denotes in vivo engraftment.
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abrogated haematopoietic specification of hESCs, which fur-
ther supports its key role in that process. Thus, in contrast
to the conflicting findings in the murine system, studies in
the hESC system suggest that TAL1 is essential both for the
establishment of the HE and its subsequent haematopoietic
commitment and is a good candidate for forward program-
ming strategies.
RUNX1 (AML1, CBFA2, PEBP2aB) is essential for the
establishment of the definitive haematopoietic system during
development and is a key transcriptional regulator of normal
and malignant haematopoiesis (Chen et al, 2009; Lam &
Zhang, 2012; Liakhovitskaia et al, 2014). While there are at
least 12 different mRNA isoforms, three main protein iso-
forms (RUNX1A/B/C) are most well studied. Overexpression
of RUNX1A using constitutive lentiviral transduction in a
defined spin EB differentiation system significantly enhanced
haematopoietic differentiation of human PSCs (Ran et al,
2013). Gene expression analysis revealed that RUNX1A
forced lineage commitment to mesoderm and specifically
enhanced haemogenic differentiation. There was expansion
of HPCs and establishment of ‘definitive HSCs’ as evidenced
by higher b globin expression and multilineage in vivo
engraftment of immunodeficient (NSG) mice at 9 weeks.
However, while these in vivo engraftment results were extre-
mely promising, there remains the possibility that the
engraftment could have been due to RUNX1A-mediated
transformation of hESC-derived cells, particularly given it is
known to contribute to leukaemogenesis (Real et al, 2013).
In these experiments RUNX1A was expressed at very high,
non-physiological levels (>700-fold higher than normal) and
the RUNX1A-expressing CD45+CD34+ cells showed a sur-
prisingly greater rate of expansion (>25-fold) compared to
their CD34+ UCB-derived counterparts. RUNX1A-expressing
cells were limited in their terminal differentiation capacity
with approximately 80% of the CD45+ cells retaining the
CD34 marker, indicating that they retained a progenitor-like
phenotype. Furthermore, although 100% of the analysed
mice showed some level of engraftment, multilineage analysis
revealed that only a relatively small proportion of the
engrafted cells expressed mature haematopoietic cell markers
(~11% myeloid, 8% lymphoid, 5% erythroid), indicating that
over 70% of the repopulation consisted of undifferentiated
progenitors.
In another study using an OP9 co-culture differentiation
system, the emergence of haematopoietic cells was shown to
parallel more closely to the expression of the RUNX1C,
rather than the RUNX1A isoform but while overexpression
of RUNX1C also accelerated and enhanced the production of
haemato-endothelial cells, no in vivo engraftment was
detected (Real et al, 2013). Hence, although RUNX1A over-
expression holds promise as a potential forward program-
ming factor for in vitro HSC production, further studies are
required to investigate its possible transformation potential.
This issue could be addressed using an inducible rather than
constitutive expression system or by using cell-permeable
proteins rather than lentiviral transduction of cDNA
sequences. Exemplified by the use of HOXB4-TAT proteins
(Krosl et al, 2003), such cell-permeable TFs would have a
limited half-life and oncogenic transformation and/or inser-
tional mutagenesis associated with genomic integration
would be avoided.
SOX17 (Sry box 17) plays a role in a number of develop-
mental processes, including endoderm (Hudson et al, 1997;
Kanai-Azuma et al, 2002) and vascular development (Matsui
et al, 2006), and has been shown to be important for the reg-
ulation of murine fetal and neonatal, but not adult, HSCs.
Overexpression of SOX17 has been reported to confer fetal
characteristics onto adult HPCs (He et al, 2011). To identify
genes promoting haematopoietic development of hPSCs,
genes encoding 13 TFs known to be haematopoietic regula-
tors (including RUNX1, GATA2, HOXB4, TAL1, SOX17)
were overexpressed in hESC/iPSC-derived CD34+CD43
endothelial cells (Nakajima-Takagi et al, 2013). SOX17 was
found to be the only TF that promoted cell growth and sup-
ported the expansion of CD34+43+45/low cells expressing
the HE marker, CD144 (VE-Cadherin). SOX17 was expressed
at higher levels in CD34+43 cells compared to
CD34+43+45 (‘pre-HPCs’) and CD34+43+45+ (‘HPCs’).
Overexpression of SOX17 promoted expansion of HE-like
cells but inhibited haematopoietic differentiation of pre-
HPCs and HPCs and reprogrammed them into HE-like cells,
while depletion of SOX17 in pre-HPCs did not affect their
haematopoietic differentiation. Hence, this study suggests
that SOX17 is a master regulator of HE but must be down-
regulated thereafter to allow haematopoietic differentiation
to occur. The use of SOX17 in a forward programming strat-
egy to generate haematopoietic cells from iPSCs will there-
fore require an expression strategy that will allow it to be
switched on and off at the appropriate time during the dif-
ferentiation protocol.
HOXB4 belongs to the homeobox-containing class of pro-
teins that are well known to play an important role in
haematopoietic development (Alharbi et al, 2013). Enforced
expression of HOXB4 results in the expansion of adult HSCs
ex vivo (Antonchuk et al, 2002; Schiedlmeier et al, 2003) and
has been shown to confer long-term reconstitution ability on
primitive yolk sac cells and mouse ESCs (Kyba et al, 2002).
It is widely reported to enhance the production of
haematopoietic cells from murine ESCs and its activity
appears to be mediated both via cell autonomous & para-
crine mechanisms (Jackson et al, 2012). However, its effect
on the differentiation of hESCs is less clear. Variable results
in hESC studies are likely to be due to the different strategies
used to express HOXB4 protein resulting in differing levels
of expression and the variety of differentiation systems
employed (Forrester & Jackson, 2012). Using a well-defined
serum-free, feeder-free hPSC differentiation system and an
inducible expression strategy, our group has recently shown
that activation of an inducible HOXB4-ERT2 fusion protein
enhanced the production of multipotential progenitors, it
Review
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has no effect on subsequent erythroid maturation and hence
failed to produce a more ‘definitive’ phenotype (Jackson
et al., 2016).
HOXA9 is another homeobox-containing protein that
plays a crucial role in haematopoiesis in vivo. It is expressed
in HPCs and is downregulated upon differentiation, knock-
out mice display significant haematopoietic defects and it is
frequently overexpressed in human leukaemias (Alharbi et al,
2013). In a study to compare the expression profiles of
hESC-derived and cord blood-derived HPCs, HOXA9 was
found be to expressed at a significantly lower level in hESC-
derived HPCs and so was considered as one of the factors
that could be used to improve the function of hESC-derived
cells (Ramos-mejia et al, 2014). Using a lentiviral expression
system this study demonstrated that enforced expression of
HOXA9 in hESCs promoted the commitment of haemogenic
precursors (CD31+CD34+CD45) to clonogenic HPCs and
mature CD45+ cells. However, HOXA9 alone was not suffi-
cient to confer in vivo long-term engraftment potential to
hESC-derived HPCs, reinforcing the notion that multiple TFs
will be required for the production of definitive HSCs from
human PSCs.
Through ectopic expression of TFs in various
haematopoietic differentiation systems, the studies reviewed
here have affirmed their key role in haematopoiesis and have
revealed important insights into the process of human
haematopoietic development. Importantly however, apart
from the potentially promising results with RUNX1A, the
overexpression of single TFs has so far failed to produce
in vivo engraftable HSCs. Given the complex nature of
haematopoietic commitment, it is perhaps not surprising
that a single TF alone could not initiate the entire
haematopoietic programme.
Forward programming of human PSCs with
multiple transcription factors
The concomitant overexpression of multiple TFs was
employed to elucidate the transcriptional control of HE pro-
duction. For this, 27 candidate genes were screened that were
known from the literature to be key transcriptional regulators
of both mesodermal and angio-haematopoietic specification
as well as HSC development itself (Elcheva et al, 2014).
Using both lentiviral transduction and overexpression of
modified mRNA, two distinct haemato-endothelial pro-
grammes in differentiating hPSCs were demonstrated: pan-
myeloid (ETV2 and GATA2) and erythro-megakaryocytic
(GATA2 and TAL1). Both combinations induced human
PSCs directly to HE but with differing capacities for further
lineage specification. Hence, this suggests that the specifica-
tion to discrete HPCs starts at the HE stage and is regulated
by distinct transcriptional programmes. It is an interesting
reflection that although complex genetic networks are
undoubtedly involved in haematopoiesis, yet such a small
subset of transcriptional regulators are capable of activating a
TF network leading to HE formation with different func-
tional capacities.
Multiple TFs were also used to convert lineage-restricted
progenitors derived from human PSCs (CD34+45+ myeloid
precursors) to multipotential progenitors (Doulatov et al,
2013). Candidate TFs were initially selected based on those
more highly expressed in HSCs compared to HPCs or
mature cells in mouse & human gene expression data sets.
An in vitro screen for self-renewal capacity based on detect-
ing clonogenic progenitors by serial plating was then
employed. HOXA9, ERG and RORA were identified as con-
ferring self-renewal capacity when overexpressed in vitro.
Using an inducible lentiviral system, ectopic expression of
two additional factors, SOX4 and MYB, conferred short-term
engraftment of the myeloid and erythroid lineages in vivo
and the erythroid precursors underwent haemoglobin switch-
ing in vivo. However, despite obtaining T lymphoid potential
in vitro, no lymphoid engraftment could be demonstrated
in vivo and the overall engraftment level waned with time.
Future perspectives
Transcription factor programming is a relatively new
approach to the production and expansion of HSC/HPCs
and our experience in human cells is still in its infancy.
While the studies described in this review have undoubtedly
progressed the field, we are still some way from achieving
large-scale production of HSCs and functional mature blood
cells that could be used safely in the clinic.
To date, fully functional HSCs capable of long-term multi-
lineage engraftment and secondary transplantation have only
being achieved in the mouse using the in vivo microenviron-
ment for selection of HSCs (Riddell et al, 2014). The lack of
success in generating fully functional HSCs probably reflects
a failure to precisely recapitulate the in vivo developmental
process. Mammalian embryonic haematopoiesis occurs in
three waves within discrete anatomical niches (Yoder, 2014)
and it is proposed that the ‘immature’ nature of human
PSC-derived cells (e.g. production of nucleated RBCs with
fetal rather than adult globin) may be due to them arising
from the first or second wave of haematopoiesis rather than
the third ‘definitive’ wave. Current knowledge of human
embryonic haematopoiesis is largely extrapolated from ani-
mal models and until recently we have lacked a clear under-
standing of a stepwise route to HSC production in vivo. The
recent identification of surface markers of HSCs and their
precursors (Rybtsov et al, 2011, 2014; Ivanovs et al, 2014)
will provide vital reference points for their future production
in vitro. The exact orchestration of both intrinsic and extrin-
sic signals mimicking the complex spatial, temporal and
mechanical environment of the human embryo must be pre-
sent if we are to produce HSCs in vitro.
Development of reprogramming technologies in well-
defined serum-free, good manufacturing practice-compliant
human haematopoietic differentiation systems is essential if
Review
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they are to be readily transferable to the clinic. Many of the
differentiations systems used in studies to date have included
serum or xenobiotic feeder cells that could not be directly
translated into a therapeutic protocol.
In addition, many of the TFs used in the studies reviewed
here are proto-oncogenes and it is very likely that successful
programming to HSCs will involve alteration of genetic net-
works common to both stem and cancer cells. This clearly
raises important safety considerations as we move closer to
clinical applications. Overexpression of a single TF is less
likely to lead to malignant transformation as a ‘single hit’,
without other co-existent mutations. Yet the studies
described suggest that overexpression of multiple TFs is likely
to be more successful.
Thus the use of inducible expression strategies will be vital
for ensuring only transient overexpression of TFs and to
limit the oncogenic transformation of the cells produced.
Most of the studies discussed have predominantly employed
lentiviruses, which are randomly integrated into the genome
and therefore may disrupt genome integrity and/or enhance
oncogenic potential.
In the studies described here TFs were selected based on
their known role in haematopoiesis or using a variety of
screening strategies (Table I) and have paved the way for fur-
ther in vitro and in vivo screening for TF combinations to be
tested. Future screening studies will benefit from using more
sophisticated genome editing strategies such as the integra-
tion of transgenes into the AAVS locus using the CRISPR/
CAS9 system to ensure robust and consistent expression
(Sadelain et al, 2012). This locus provides a ‘safe harbour’,
which avoids insertional mutagenesis that can occur using a
random integration system. Ultimately, non-integrative
strategies that result in transient protein expression such as
synthetic modified mRNA, non-integrating plasmids (Bernal,
2013) and cell-permeable TFs, as discussed earlier, could be
safer alternatives.
Exciting advances in the production of synthetic TFs such
as zinc finger, TALE and CAS9 proteins are likely to provide
even more sophisticated tools to modulate the expression of
endogenous genes that could bypass the need for transgene
insertion altogether (Hockemeyer et al, 2011; Miller et al,
2011). For example, variant CAS9 proteins have been devel-
oped that can be directed to the regulatory regions of gene
promoters using complementary guide RNAs and, when
tethered to transcriptional activators (e.g VP64), they are able
to activate the expression of that target gene (Gilbert et al,
2014; Sander & Joung, 2014). Very recently this strategy has
been used to induce neuronal differentiation of human iPSCs
via the activation of NEUROG2 and NEUROD1 (Chavez
et al, 2015) and to improve directed differentiation to pan-
creatic progenitor-like cells by activating simultaneously
SOX17, FOXA2, PDX1 and NKX6-1 (Balboa et al, 2015).
This may well be an effective and safer strategy for forward
programming PSCs into blood cell lineages.
The use of new programming technologies in combination
with a better understanding of the inductive environment
and the precise phenotype of the desired cell type may well
lead to new breakthroughs during the next decade and bring
us closer to the overall goal of the in vitro production of
fully functional HSCs for use in the clinic.
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